LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
Lunai Bioworks (Nasdaq:LNAI) will implement a 1-for-8 reverse stock split of its common stock, effective 12:01 a.m. ET on May 22, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lunai Bioworks (Nasdaq:LNAI) will implement a 1-for-8 reverse stock split of its common stock, effective 12:01 a.m. ET on May 22, 2026. Shares will begin trading on a split-adjusted basis that day under LNAI with new CUSIP 29350E302.
The split, approved by stockholders and set by the board, is intended to increase the per-share price to help regain compliance with Nasdaq Listing Rule 5550(a)(2). Outstanding shares will decline from about 36.27 million to about 4.53 million, with no change to par value or authorized shares, and fractional shares rounded up.
Positive
- Reverse split aims to support Nasdaq $1.00 minimum bid compliance
- Outstanding shares reduced from ~36.27M to ~4.53M
- No change to authorized share count or par value
- Fractional shares rounded up to the next whole share
Negative
- Company previously executed a 1-for-10 reverse split on Sept. 30, 2025
- Reverse split signals prior share price below Nasdaq minimum bid level
Details
News Market Reaction – LNAI
On May 20, the day this news came out, LNAI closed 10.19% below the previous close.
Data tracked by StockTitan Argus for the May 20 session.
Key Figures
- Reverse split ratio
- 1-for-8
- Reverse stock split of common stock
- Effective date
- May 22, 2026
- Reverse stock split effective at 12:01 a.m. ET
- Pre-split shares
- 36,271,119 shares
- Issued and outstanding common stock before split
- Post-split shares
- 4,533,890 shares
- Issued and outstanding common stock after split
- Prior reverse split
- 1-for-10
- Reverse stock split effected on September 30, 2025
- Nasdaq minimum bid
- $1.00 per share
- Nasdaq Listing Rule 5550(a)(2) requirement
- Par value
- $0.0001 per share
- Par value of common stock, unchanged by split
Historical Context
-
Completed $20M Series B preferred issuance to acquire CNS delivery and IP.
-
Subsidiary signed LOI to build rare disease cohorts for pharma partnerships.
-
Announced multi-year, revenue-generating defense collaboration using AI platform.
-
Executed $20M deal for BBB CNS platform via fixed-price convertible preferred.
-
Launched national chemical defense consortium targeting large U.S. programs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
reverse stock split financial
CUSIP regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Company's Common Stock will trade under a new CUSIP number, 29350E302 following the effectiveness of the Reverse Stock Split.
At the Company's Special Meeting of Stockholders held on May 8, 2026, the Company's stockholders approved a proposal authorizing the Company's Board of Directors to amend the Company's Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio in the range of 1-for-3 to 1-for-30, inclusive, with the exact ratio to be determined by the Board in its sole discretion and publicly announced prior to the effective time of the Reverse Stock Split. The Board of Directors subsequently approved the final 1-for-8 Reverse Stock Split ratio.
The Reverse Stock Split is intended primarily to increase the market price per share of the Company's Common Stock to assist the Company in regaining compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of at least
As a result of the Reverse Stock Split, every 8 shares of issued and outstanding Common Stock will automatically be combined into one issued and outstanding share of Common Stock. The Reverse Stock Split will not change the par value of the Common Stock or the number of authorized shares of Common Stock. The Reverse Stock Split will reduce the number of issued and outstanding shares of Common Stock from approximately 36,271,119 shares to approximately 4,533,890 shares, subject to adjustment for the treatment of fractional shares.
No fractional shares will be issued in connection with the Reverse Stock Split. Any fractional share that would otherwise result from the Reverse Stock Split will be automatically rounded up to the next whole share at the registered stockholder or DTC participant level, as applicable. Registered stockholders holding shares in book-entry form will receive information from the Company's transfer agent regarding their post-split holdings. Beneficial owners holding shares through a bank, broker or other nominee will have their positions adjusted in accordance with the procedures of their bank, broker or nominee.
The Company's transfer agent, Securities Transfer Corporation, will act as exchange agent for the Reverse Stock Split. Stockholders holding shares electronically in book-entry form are not required to take any action to receive post-split shares.
Proportionate adjustments will be made, as appropriate and in accordance with the terms of the applicable instruments, to the number of shares of Common Stock issuable upon the exercise, vesting, conversion or exchange of our outstanding options, warrants, restricted stock units and other convertible or exercisable securities, as well as to the exercise or conversion prices thereof and to share reserves under our equity compensation plans.
Lunai Bioworks (Nasdaq: LNAI) is an AI-driven life sciences company advancing drug discovery and chemical defense through its integrated platform. Lunai combines clinical data, machine learning, and in vivo validation to identify disease biology and develop precision therapeutics. The Company is focused on central nervous system diseases and oncology, with a mission to reduce development timelines and improve clinical success rates.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the expected timing and effectiveness of the Reverse Stock Split, the expected commencement of split-adjusted trading, the Company's ability to regain or maintain compliance with Nasdaq continued listing requirements, and the expected effects of the Reverse Stock Split on the Company's capitalization, trading price, liquidity and stockholders. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks that the Reverse Stock Split may not result in a sustained increase in the market price of the Common Stock; may result in reduced liquidity, wider bid-ask spreads or increased volatility; may not enable the Company to regain or maintain compliance with Nasdaq Listing Rule 5550(a)(2) or other Nasdaq continued listing requirements; may be subject to Nasdaq, FINRA, DTC or other processing delays; and may be affected by general market conditions, trading prices, investor acceptance and the determinations of the Nasdaq Hearings Panel. Additional risks and uncertainties are described in the Company's filings with the
View original content to download multimedia:https://www.prnewswire.com/news-releases/lunai-bioworks-inc-announces-reverse-stock-split-302777713.html
SOURCE Lunai Bioworks Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.